NCT03449030View on ClinicalTrials.gov

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

PHASE1TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

February 27, 2020

Study Completion Date

February 27, 2020

Conditions
Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
Interventions
DRUG

TAK-164

TAK-164 intravenous infusion.

DRUG

89Zr-TAK-164

89Zr-TAK-164 intravenous infusion

Trial Locations (4)

33612

Moffitt Cancer Center, Tampa

37205

SCRI - Tennessee Oncology Nashville - Southern Hills Clinic, Nashville

80045

University of Colorado Cancer Center, Aurora

02114-2621

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY